Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Other Accumulated Expenses (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Other Accumulated Expenses for 6 consecutive years, with $196000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 157.89% to $196000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $196000.0 through Dec 2025, up 157.89% year-over-year, with the annual reading at $196000.0 for FY2025, 157.89% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $196000.0 at TScan Therapeutics, up from $189000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $1.3 million in Q3 2022, with the low at $76000.0 in Q4 2024.
  • Average Other Accumulated Expenses over 5 years is $438789.5, with a median of $425000.0 recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses surged 666.67% in 2021, then crashed 82.12% in 2024.
  • Over 5 years, Other Accumulated Expenses stood at $1.0 million in 2021, then crashed by 57.41% to $431000.0 in 2022, then fell by 1.39% to $425000.0 in 2023, then plummeted by 82.12% to $76000.0 in 2024, then surged by 157.89% to $196000.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $196000.0, $189000.0, and $190000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.